Putting the IMPACT study into perspective: Should CMV prophylaxis be extended to 6 months for high risk transplants?

American Journal of Transplantation

Volumn 11, Issue 1, 2011, Pages 6-7

  Snydman, D R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS INFECTION; EDITORIAL; HIGH RISK POPULATION; INFECTION PREVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSPLANTATION; TREATMENT DURATION; ADULT; HUMAN; PROPHYLAXIS;

CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; ORGAN TRANSPLANTATION;

EID: 78650856520     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03353.x     Document Type: Editorial

References (9)

1. Limaye AP, Bakthavatsalam R, Kim HW, et al,. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 1390-1396.
2. Humar A, Lebranchu V, Vincenti F, et al,. The efficicacy and safety of 200 days of Valganciclovir Cytomegalovirus Prophylaxis in high-risk Kidney Transplant Recipients. Am J Transplant 2010; 10: 1228-1237.
3. Kalil AC, Sun J, Florescu DF,. IMPACT trial results should not change current standard of care of 100 days cytomegalovirus prophylaxis. Am J Transplant 2011; 11: 18-21.
4. Helantera I, Lautenschlager I, Koskinen P,. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009; 24: 316-320.
5. Humar A, Limaye AP, Blumberg E, et al,. Extending valganciclovir prophylaxis in kidney transplant high risk (D+/R-) recipients is associated with long-term benefits: Two year results from the IMPACT study. Transplantation 2011. In press.
6. Palmer SN, Limaye AP, Banks M, et al,. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation. A randomized, controlled trial. Ann Int Med 2010; 152: 761-769.
7. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus infection in solid organ transplantation. Transplantation 2010; 89: 775-795.
8. Valentine VG, Weill D, Gupta MR, et al,. Ganciclovir for Cytomegalovirus: A Call for Indefinite Prophylaxis in Lung Transplantation. J Heart Lung Transplant 2008; 27: 875-881.
9. Kleim V, Fricke L, Wollbrink T, et al,. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir or valganciclovir prophylaxis. Am J Transplant 2008; 8: 975-983.